This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Zydus September 2026 quarter: revenue up 29 percent, profit down 27 percent
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts less than Nifty 100 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated results, quarter ended September 30, 2026: revenue from operations rose 29 percent to INR 79,096 million from INR 61,232 million a year ago, and net profit fell 27 percent to INR 9,255 million from INR 12,609 million. EBITDA margin fell from 32.4 percent to 24.3 percent. Exceptional items: net gain INR 13 million. Prior profit updated for purchase price allocation. Standalone: revenue INR 34,820 million, profit INR 7,145 million.
Acquisitions drove much of the revenue rise, but profit fell and margins narrowed sharply; near-term earnings sentiment may weigh on the stock.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹7,910 Cr | ₹6,123 Cr | +29.2% |
| Operating profit | ₹1,103 Cr | ₹1,613 Cr | −31.6% |
| Profit after tax | ₹927.7 Cr | ₹1,239 Cr | −25.1% |
| EBITDA margin | 24.0% | 32.4% | −8.4 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.